AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN ANTONIO -- Being on hormone therapy at the time breast cancer is diagnosed doesn't adversely affect prognosis, Dr. Nigel J. Bundred reported at a breast cancer symposium sponsored by the Cancer Therapy and Research Center.
He presented a retrospective comparison of outcomes in 1,049 breast cancer patients who had never used hormone therapy (HT) and 558 who were receiving HT at the time of diagnosis. All participants were aged 50-65 years when they were diagnosed at the Manchester (England) Breast Screening Unit. A total of 962 women had nonpalpable cancers detected via screening mammography; the remainder were symptomatic.
HT users were significantly more likely to have tumors with favorable pathologic features. For example, 57% of them had tumors less than 1.5 cm in size, compared with 49% of nonusers. Grade I tumors were present in 38% of HT users, compared with 22% of nonusers. And 90% of HT users had estrogen receptor-positive tumors potentially responsive to adjuvant endocrine therapy, compared with only 71% of nonusers. Moreover, prognostically less favorable grade III tumors were present in only 19% of HT users, compared with 38% of nonusers, added Dr. Bundred of ...
Source: HighBeam Research, Hormone therapy at breast Ca diagnosis: no adverse effect on...